LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

About this update from Lb Pharmaceuticals Inc

NEW YORK , April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced that Heather Turner , Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 , at 11:45 a.m. ET . A live webcast of the presentation will be available on the “Investors” page under the “Events” section of the Company’s website at https://ir.lbpharma.us/investors/events/ , where a replay of the webcast will be archived. About LB Pharmaceuticals LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive MDD, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States . LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a wide range of neuropsychiatric diseases. Media and Investor Contact Ellen Rose [email protected] Source: LB Pharmaceuticals Inc

View stock analysis, news, and events for Lb Pharmaceuticals Inc